NCT02448719 - Single-Dose Phase 1 Study of TAK-792 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2015

Primary Completion Date

January 28, 2016

Study Completion Date

January 28, 2016

Conditions

Healthy Male Adults Participants

Interventions

DRUG

TAK-792 30 mg

TAK-792 30 mg was administered in the morning after a fast.

DRUG

TAK-792 30 mg placebo

TAK-792 30 mg placebo was administered in the morning after a fast.

DRUG

TAK-792 100 mg

TAK-792 100 mg was administered in the morning after a fast.

DRUG

TAK-792 100 mg placebo

TAK-792 100 mg placebo was administered in the morning after a fast.

DRUG

TAK-792 250 mg

TAK-792 250 mg was administered in the morning after a fast.

DRUG

TAK-792 250 mg placebo

TAK-792 250 mg placebo was administered in the morning after a fast.

DRUG

TAK-792 500 mg

TAK-792 500 mg was administered in the morning after a fast or after breakfast.

DRUG

TAK-792 500 mg placebo

TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.

DRUG

TAK-792 750 mg

TAK-792 750 mg was administered in the morning after a fast.

DRUG

TAK-792 750 mg placebo

TAK-792 750 mg placebo was administered in the morning after a fast.

DRUG

TAK-792 1250 mg

TAK-792 1250 mg was administered in the morning after a fast.

DRUG

TAK-792 1250 mg placebo

TAK-792 1250 mg placebo was administered in the morning after a fast.

Trial Locations (1)

Unknown

Kagoshima